Crossmark

Association of chemotherapy and comorbidities with overall survival in elderly patients with early breast cancer: a French population-based propensity score-matched analysis

Crossref DOI link: https://doi.org/10.1007/s10147-023-02296-z

Published Online: 2023-01-16

Published Print: 2023-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Corbaux, Pauline https://orcid.org/0000-0001-8832-2562
Terret, Catherine

Cropet, Claire

Chabaud, Sylvie

Russo, Chiara

Faure, Christelle

Tredan, Olivier

Bachelot, Thomas

Heudel, Pierre-Etienne https://orcid.org/0000-0002-2155-549X
License Information

Text and Data Mining valid from 2023-01-16

Version of Record valid from 2023-01-16
More Information

Article History

Received: 28 September 2022

Accepted: 9 January 2023

First Online: 16 January 2023

Declarations

:

: Dr Bachelot has received compensation for his advisory role for Astra Zeneca, Novartis, Pfizer, Roche and SeaGen. He also has received research support from Roche, Pfizer, SeaGen and Astra Zeneca. Dr Corbaux, Dr Terret, Mrs Cropet, Mrs Chabaud, Dr Russo, Dr Faure, Dr Tredan and Dr Heudel declare no potential competing interests in relation with this work.

Document is current

Any future updates will be listed below